PTC Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $196,786 | $186,704 | $210,118 | $307,056 |
Gross Profit | 185,938 | 168,312 | 143,848 | 200,764 |
EBITDA | -49,896 | -35,225 | 11,533 | -32,071 |
EBIT | -56,382 | -42,243 | -43,862 | -112,776 |
Net Income | -106,654 | -99,179 | -91,576 | -155,792 |
Net Change In Cash | 196,786 | 186,704 | 210,118 | 307,056 |
Free Cash Flow | -22,751 | -64,078 | 6,410 | -128,750 |
Cash | 526,001 | 654,779 | 548,355 | 594,001 |
Basic Shares | 76,925 | 76,725 | 76,496 | 75,510 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $937,822 | $698,801 | $538,593 | $380,766 |
Gross Profit | 872,336 | 654,123 | 506,265 | 361,824 |
EBITDA | -330,340 | -367,780 | -374,443 | -297,004 |
EBIT | -566,930 | -496,616 | -445,963 | -346,580 |
Net Income | -626,604 | -559,017 | -523,901 | -438,160 |
Net Change In Cash | 937,822 | 698,801 | 538,593 | 380,766 |
Cost of Revenue | 101,479 | -11,273 | -86,904 | |
Free Cash Flow | -279,037 | -509,114 | -336,663 | -250,048 |
Cash | 594,001 | 410,705 | 773,376 | 208,812 |
Basic Shares | 74,838 | 71,728 | 70,466 | 66,027 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.39 |
2024-06-30 | -$1.27 |
2024-03-31 | -$1.20 |
2023-12-31 | -$0.24 |
